Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197868 | 0.91 | CHRM1 (0.50) | HRH3KCNH2CYP2D6CHRM1CHRNA7 | |
| SCHEMBL16577148 | 0.86 | KDM4E (0.46) | HRH3KCNH2CYP2D6CHRM1KDM4E | |
| SCHEMBL7992803 | 0.86 | HRH3 (0.38) | HRH3KCNH2CYP2D6CHRM1CHRNA7 | |
| SCHEMBL28287189 | 0.84 | CHRNA7 (0.46) | HRH3KCNH2CYP2D6CHRM1CHRNA7 | |
| SCHEMBL10250886 | 0.83 | HRH3 (0.47) | HRH3KCNH2CYP2D6CHRM1CHRNA7 | |
| SCHEMBL26680011 | 0.82 | HRH3 (0.66) | HRH3KCNH2CYP2D6CHRNA7ALDH1A1 | |
| SCHEMBL27853492 | 0.81 | KMT2A (0.35) | HRH3KCNH2CYP2D6CHRM1KDM4E | |
| SCHEMBL4487226 | 0.81 | HRH3 (0.46) | HRH3KCNH2CYP2D6ALDH1A1 | |
| SCHEMBL4475509 | 0.80 | HRH3 (0.49) | HRH3KCNH2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL1105150 | 0.80 | CYP1A2 (0.54) | HRH3KCNH2CYP2D6CHRM1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875016-B1 | CARBAMATE/UREA DERIVATIVES | NOVARTIS AG (CH) | 2017-08-23 | — | — | EP | claimed |
| EP-2763978-B1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2017-02-01 | — | — | EP | claimed |
| EP-2938600-B1 | COMT INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-01-25 | — | — | EP | claimed |
| WO-2013050987-A9 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2013-07-25 | — | — | WO | claimed |
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | claimed |
| US-7626040-B2 | Substituted imidazole compounds as KSP inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | claimed |
| CN-100528871-C | Benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | claimed |
| CN-101253167-A | Substituted imidazole compounds as KSP inhibitors | NOVARTIS VACCINES & DIAGNOSTIC (CH) | 2008-08-27 | — | — | CN | claimed |
| US-7371748-B2 | Benzothiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | claimed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | claimed |
| CN-1791600-A | Benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | claimed |
| EP-1636223-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2006-03-22 | — | — | EP | claimed |
| CN-1602196-A | Ureas of 2-aminobenzothiazoles as adenosine modulators | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | CN | claimed |
| WO-2005000842-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040235915-A1 | Benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | claimed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | claimed |
| EP-1455792-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | claimed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | claimed |
| WO-2003049741-A1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | HRH3 1294/4885KCNH2 2241/4885CYP2D6 757/4885 |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | KIF5B, KIF2C, KIF18B | HRH3 4097/4885KCNH2 642/4885CYP2D6 3132/4885 |
| US-20040235915-A1 | Benzothiazole derivatives | ADORA1, ADORA2A, ADORA3 | HRH3 641/4885KCNH2 1231/4885CYP2D6 890/4885 |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | HRH3 1294/4885KCNH2 2241/4885CYP2D6 757/4885 |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | HRH3 115/4885KCNH2 517/4885CYP2D6 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.